Transcripta Bio Raises $24 Million in Series A Funding
Palo Alto, California-based Transcripta Bio has successfully raised $24 million in a Series A funding round. The company is dedicated to drug discovery at the biological level, utilizing the transcriptome to identify groundbreaking medicines. This latest funding round will help bolster their efforts in developing treatments for neurological and neuromuscular diseases.
Investors and Leadership
The funding saw participation from Mayo Clinic, Omnimed, JAZZ Venture Partners, BlueYard Capital, and various life sciences family offices. Although the round did not have a lead investor, the involvement of these prominent entities highlights the confidence in Transcripta Bio's innovative approach.
Founded by Christopher Moxham, with Onno Faber serving as CEO, Transcripta Bio is focused on leveraging artificial intelligence to advance its drug discovery processes. "We are excited to push forward with our research and move closer to clinical trials," said CEO Onno Faber.
Focus on Neurological and Neuromuscular Diseases
Transcripta Bio is currently working on a portfolio that includes programs targeting Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD), Autism Spectrum Disorder (ASD), and Huntington's Disease (HD). The company plans to utilize the new funds to advance IND-enabling studies across these programs. This will include preparation for clinical trials, particularly in their ASD and FSHD initiatives.
Strategic Use of Funds
The $24 million raised will be pivotal in supporting Transcripta Bio's goal to transition from discovery to clinical application. The company aims to enhance its research capabilities and accelerate the development of its drug candidates. The funds will specifically be used to advance studies that are crucial for obtaining Investigational New Drug (IND) status, a significant step towards human clinical trials.
Future Outlook
With this infusion of capital, Transcripta Bio is well-positioned to make significant strides in the field of drug discovery for complex diseases. The support from a diverse group of investors underscores the potential impact of their work on future medical treatments.
As Transcripta Bio continues its journey, the focus will remain on harnessing the power of the transcriptome to bring innovative solutions to the forefront of medical science. The company's progress in the coming months will be closely watched by both the scientific community and investors alike.